IGF1 and Miyoshi myopathy: It was shown that bortezomib-resistant myeloma cell lines and clinical samples from bortezomib-refractory MM patients displayed an activated IGF-1/IGF-1R signaling pathway and a high level of IGF-1 cytokine which were associated with bortezomib resistance.